<DOC>
	<DOCNO>NCT01512446</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety bisphosphonates long term treatment osteoporosis .</brief_summary>
	<brief_title>Comparison Effect Ongoing Treatment With Alendronate Drug Holiday Fracture Risk Osteoporotic Patients With Bisphosphonate Long Term Therapy</brief_title>
	<detailed_description>Is continue treatment alendronate another two year precede therapy bisphosphonates least four year able reduce incidence new osteoporotic fracture patient high fracture risk compare therapy-free interval ?</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Postmenopausal woman men &gt; 60 year DXA TScore lumbar spine , total hip femur neck &lt; 2,0 start bisphosphonate therapy baseline least one low trauma vertebral fracture grade 23 multiple low trauma vertebral fracture independent bone mineral densitiy Pretreatment bisphosphonates least four year Risk hip vertebral fracture min . 30 % accord DVOguideline osteoporosis 2009 Signed inform consent Other pharmacological treatment osteoporosis last 48 month Other bone diseases Malabsorption syndromes Renal insufficiency calculate creatinine clearance &lt; 35 ml/min Diseases esophagus , delay esophageal clearance UUnability realise intake instruction Hypocalcemia</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Osteoporotic fracture</keyword>
	<keyword>Bisphosphonate</keyword>
	<keyword>Pretreatment bisphosphonates</keyword>
</DOC>